RVMD icon

Revolution Medicines

35.67 USD
-1.34
3.62%
At close Aug 25, 4:00 PM EDT
1 day
-3.62%
5 days
-2.97%
1 month
-5.91%
3 months
-3.54%
6 months
-13.72%
Year to date
-18.93%
1 year
-19.04%
5 years
26.49%
10 years
23.43%
 

About: Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Employees: 700

0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

71% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 34

27% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 88

18% more call options, than puts

Call options by funds: $29.4M | Put options by funds: $24.8M

7% more funds holding

Funds holding: 281 [Q1] → 300 (+19) [Q2]

3% more capital invested

Capital invested by funds: $6.78B [Q1] → $7.01B (+$231M) [Q2]

0.52% less ownership

Funds ownership: 102.77% [Q1] → 102.25% (-0.52%) [Q2]

14% less funds holding in top 10

Funds holding in top 10: 21 [Q1] → 18 (-3) [Q2]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$56
57%
upside
Avg. target
$71
98%
upside
High target
$80
124%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
Kelsey Goodwin
110%upside
$75
Overweight
Initiated
19 Aug 2025
LifeSci Capital
124%upside
$80
Outperform
Initiated
18 Aug 2025
Wells Fargo
88%upside
$67
Overweight
Initiated
15 Aug 2025
Needham
Ami Fadia
57%upside
$56
Buy
Maintained
7 Aug 2025
Goldman Sachs
Andrea Newkirk
82%upside
$65
Buy
Initiated
15 Jul 2025

Financial journalist opinion

Based on 4 articles about RVMD published over the past 30 days

Neutral
Seeking Alpha
2 weeks ago
Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anthony Mancini - Chief Global Commercialization Officer Jack Anders - Chief Financial Officer Mark A. Goldsmith - CEO, President & Chairman Ryan Asay - Senior Vice President of Corporate Affairs Stephen M.
Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2025, and provided an update on corporate progress.
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Neutral
GlobeNewsWire
3 weeks ago
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2025 on Wednesday, August 6, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
Positive
Zacks Investment Research
4 weeks ago
Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Revolution Medicines (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade
Neutral
GlobeNewsWire
1 month ago
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
REDWOOD CITY, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Science. The scientific paper details the discovery and development of zoldonrasib (RMC-9805), a RAS(ON) G12D-selective covalent inhibitor.
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Neutral
GlobeNewsWire
1 month ago
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor Designation based on encouraging clinical data observed with elironrasib in patients with advanced KRAS G12C non-small cell lung cancer REDWOOD CITY, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to elironrasib, the company's RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Neutral
GlobeNewsWire
1 month ago
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates
Custom-built model will be trained using Revolution Medicines' proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near-term performance-based milestone payments for services related to Revolution Medicines' access to Iambic's industry-leading NeuralPLexer model for protein structure prediction REDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing  targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug candidates using Iambic's leading AI models.
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates
Neutral
GlobeNewsWire
1 month ago
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines' clinical-stage RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldonrasib (RMC-9805) and G12C-selective inhibitor elironrasib (RMC-6291), in combination with Summit Therapeutics' ivonescimab, a PD-1 / VEGF bispecific antibody.
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
Neutral
Business Wire
1 month ago
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
REDWOOD CITY, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinic.
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
Positive
Reuters
2 months ago
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Royalty Pharma said on Tuesday will pay up to $2 billion to Revolution Medicines to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib.
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Charts implemented using Lightweight Charts™